Managed Healthcare Executive

10/23/2025

Digital tool tied to 60% increase in lung cancer screening rates

Study participants who used the mPATH-Lung program were 60% more likely to undergo lung cancer screening, than particpants who did not use the program.

10/23/2025

These new findings could lead to advances in multiple sclerosis treatment

A greater understanding of the association between multiple sclerosis (MS) and the oral microbiome may lead to less invasive dialogistic markers and novel treatment options for patients, according to this recent study by researchers at the University of Iowa Health Care.

10/22/2025

What can subgroup analyses from the trial tell us about optimizing care for ER+/HER2– metastatic ?
Explore key findings on prior ET, CDK4/6 duration, and more in this Between the Lines episode: https://hubs.li/Q03PHKns0

10/16/2025

Monitoring patient turnover and evaluating policy changes like continuous eligibility may help improve access and affordability, authors say

Research reveals that even with over 25 million losing Medicaid during unwinding in 2023, the uninsured rate remains stable as many quickly re-enroll or switch coverage.

10/16/2025

Antibiotic resistance claims millions of lives globally each year. This report provides the latest stats

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

10/15/2025

Patients with BCG-unresponsive NMIBC have varied clinical needs that call for personalized treatment strategies. In this episode, an expert explains how P&T committees assess new therapies by examining unmet needs and comparing real-world evidence across single-arm trials.

10/15/2025

What will the most favored nation model mean for payers, providers and health systems?

Join Managed Healthcare Executive® on November 4 at 7:00 PM EST to hear experts unpack the policy’s potential ripple effects and discuss whether it could be the catalyst for lasting reform — or another experiment in pricing control.

If you can’t join the live webinar, no worries—your registration includes access to the on-demand recording, so you can watch it anytime at your convenience.

Register Here: https://hubs.li/Q03NHX-Q0

10/14/2025

At least one Shingrix dose was 56.1% effective against any shingles outcome.

A real-world analysis shows Shingrix effectively prevents shingles in adults over the age of 65, including immunocompromised people. Two doses provide better protection than one.

10/14/2025

Did you miss our second webinar on the initiative? The debate is now available to view on demand.

Watch Part 2: https://hubs.li/Q03NyvY70

If you joined us live and want more, part 3 is coming on November 4! You will have the option to engage in real time or catch the discussion on demand at your convenience.

Register Now: https://hubs.li/Q03Nyr6Y0

10/14/2025

The COVID vaccine is still effective, associated with lower risks of COVID-related outcomes over six months, study shows

A study revealed that the 2024-2025 COVID-19 vaccine significantly reduces emergency visits, hospitalizations and deaths among U.S. veterans.

10/13/2025

ICYMI: Manufacturers of branded cancer biologics are reducing their prices as a way to hold on to market share, which has limited the potential savings that health plans can realize from biosimilars, according to a study published in Health Affairs. In fact, potential savings from site-neutral payments—which reimburse hospitals at the same rate that physician practices receive—were double the potential savings from biosimilar competition.
https://hubs.li/Q03Njpss0

10/10/2025

Will Most Favored Nation (MFN) pricing lower drug costs—or slow innovation?
At the MFN 2025 webinar hosted by MJH Life Sciences, experts in health policy, law and economics talked about what could happen if the U.S. starts tying drug prices to those in other countries. Find out more below:
https://hubs.li/Q03N9pkx0